Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have been given an average rating of “Moderate Buy” by the five ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.00.

A number of analysts have weighed in on ELVN shares. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th.

Enliven Therapeutics Trading Down 10.2%

Shares of NASDAQ ELVN opened at $16.86 on Monday. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -9.16 and a beta of 0.35. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $25.37. The stock has a 50-day moving average price of $20.79 and a two-hundred day moving average price of $20.48.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, sell-side analysts predict that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $22.33, for a total transaction of $279,125.00. Following the sale, the insider directly owned 902,688 shares of the company’s stock, valued at $20,157,023.04. The trade was a 1.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $20.40, for a total transaction of $66,300.00. Following the transaction, the chief financial officer directly owned 23,000 shares of the company’s stock, valued at $469,200. The trade was a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 98,247 shares of company stock valued at $2,043,650. 25.90% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL bought a new position in Enliven Therapeutics during the 3rd quarter worth $334,000. Vestal Point Capital LP raised its position in shares of Enliven Therapeutics by 364.0% during the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after acquiring an additional 910,000 shares during the last quarter. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 1.5% in the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after acquiring an additional 44,713 shares during the period. Millennium Management LLC boosted its holdings in Enliven Therapeutics by 19.8% in the third quarter. Millennium Management LLC now owns 381,405 shares of the company’s stock valued at $7,807,000 after acquiring an additional 62,956 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Enliven Therapeutics by 10.6% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,529 shares of the company’s stock valued at $400,000 after purchasing an additional 1,873 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.